Insider Selling: LivaNova (NASDAQ:LIVN) Director Sells $273,035.00 in Stock

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 3,500 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the sale, the director directly owned 4,434 shares of the company’s stock, valued at approximately $345,896.34. The trade was a 44.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Francesco Bianchi also recently made the following trade(s):

• On Monday, August 31st, Francesco Bianchi sold 1,650 shares of LivaNova stock. The stock was sold at an average price of $79.72, for a total transaction of $131,538.00.

LivaNova Stock Performance

Shares of LIVN opened at $78.51 on Thursday. The firm has a market cap of $4.33 billion, a P/E ratio of 23.23 and a beta of 0.87. LivaNova PLC has a twelve month low of $48.82 and a twelve month high of $85.76. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45. The firm’s 50 day moving average price is $80.12 and its two-hundred day moving average price is $73.55.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.17. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The business had revenue of $390.59 million for the quarter, compared to analyst estimates of $380.50 million. During the same period last year, the business posted $1.05 earnings per share. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. On average, analysts forecast that LivaNova PLC will post 3.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on LIVN shares. Needham & Company LLC boosted their target price on LivaNova from $81.00 to $93.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Freedom Capital upgraded shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. Mizuho raised their target price on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Stifel Nicolaus set a $85.00 target price on LivaNova in a report on Wednesday, August 5th. Finally, Zacks Research lowered LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Six equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $84.12.

Institutional Trading of LivaNova

A number of hedge funds have recently made changes to their positions in LIVN. Millennium Management LLC boosted its position in LivaNova by 17.3% during the fourth quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock worth $214,376,000 after purchasing an additional 514,268 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of LivaNova by 2.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,826,248 shares of the company’s stock worth $116,067,000 after buying an additional 38,320 shares during the period. Geode Capital Management LLC grew its stake in LivaNova by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,458,838 shares of the company’s stock valued at $89,775,000 after buying an additional 12,750 shares during the last quarter. LSV Asset Management grew its stake in LivaNova by 2.7% in the 4th quarter. LSV Asset Management now owns 693,110 shares of the company’s stock valued at $42,647,000 after buying an additional 18,500 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in LivaNova by 1,978.8% in the 1st quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock valued at $29,961,000 after acquiring an additional 448,703 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and manufactures technologies for the treatment of neurological and cardiovascular conditions. The company serves hospitals, physicians and patients in markets around the world, with operations and commercial activities spanning North America, Europe and other international markets.

LivaNova’s Neuromodulation business produces vagus nerve stimulation (VNS) systems marketed under the VNS Therapy brand. These implantable devices are used as an adjunctive treatment for drug-resistant epilepsy and are designed to deliver programmed electrical stimulation to the vagus nerve.